The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GOSS | +136.7% | -77.41% | -25.73% | -88% |
| S&P | +15.06% | +95.03% | +14.29% | +149% |
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
Stock dilution is on the way for the small biotech.
Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.49M | -88.0% |
| Gross Profit | $11.28M | -88.1% |
| Gross Margin | 98.15% | -0.8% |
| Market Cap | $279.58M | 37.2% |
| Market Cap / Employee | $1.93M | 0.0% |
| Employees | 145 | 7.4% |
| Net Income | -$38.27M | -177.7% |
| EBITDA | -$38.55M | -172.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.31M | -69.7% |
| Accounts Receivable | $7.58M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $201.94M | 2.5% |
| Short Term Debt | $0.89M | -51.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -45.17% | -16.0% |
| Return On Invested Capital | -64.38% | 4.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$47.11M | 0.0% |
| Operating Free Cash Flow | -$47.06M | -140.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.74 | 3.79 | 8.45 | -44.71 | -686.22% |
| Price to Sales | 2.12 | 1.79 | 2.00 | 6.95 | 209.85% |
| Price to Tangible Book Value | 2.74 | 3.79 | 8.45 | -44.72 | -686.32% |
| Enterprise Value to EBITDA | -3.04 | -3.23 | -5.33 | -6.99 | -725.72% |
| Return on Equity | -90.3% | -122.5% | -500.6% | -783.4% | -9.27% |
| Total Debt | $203.63M | $202.88M | $202.79M | $202.83M | 1.99% |
GOSS earnings call for the period ending March 31, 2020.
GOSS earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
